2190 — Zylox-Tonbridge Medical Technology Co Balance Sheet
0.000.00%
Last trade - 00:00- HK$6.09bn
- HK$4.52bn
- CNY527.75m
- 35
- 12
- 48
- 18
Annual balance sheet for Zylox-Tonbridge Medical Technology Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 98.1 | 317 | 2,929 | 1,861 | 1,511 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 8.74 | 6.5 | 5.33 | 12.4 | 1.18 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 125 | 370 | 3,024 | 2,063 | 1,717 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 70.7 | 122 | 212 | 338 | 578 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 207 | 504 | 3,248 | 3,254 | 3,376 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 33.4 | 51.6 | 97.1 | 152 | 318 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 41.4 | 79.3 | 104 | 160 | 328 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 166 | 425 | 3,145 | 3,094 | 3,047 |
| Total Liabilities & Shareholders' Equity | 207 | 504 | 3,248 | 3,254 | 3,376 |
| Total Common Shares Outstanding |